For Investors

CureLab Oncology executive summary August 2025

CureLab Oncology company overview August 2025

Checklist
  • Experienced and dedicated team
    • comprehensive set of proven track records
    • always meeting or exceeding KPI
  • World-class advisory board
    • includes Nobel prize laureate and world leading professors
    • business experts and serial entrepreneurs with exits over $1B
    • GR experts
  • Published clinical data
    • completed phase I/IIa clinical trial
    • initiated non-US phase II clinical trial
    • Unique mechanism of action of the lead product
      • changes tumor microenvironment
      • reduces chronic inflammation
      • enhances therapeutic benefits of other treatment modalities
    • Comprehensive international IP protection
    • High anticipated ROI and short time to exit

Executive Summary
  • Immuno-oncology
    is one of the most lucrative, rapidly growing and “hungry” biomedical markets today (licensing after phase II clinical trial $1-2.4B). Nobel Prize 2018 was awarded for immuno-oncology.
  • CureLab Oncology,
    Inc. is a clinical-stage biotech company headquartered in Boston.
  • The lead product is Elenagen, an immuno-oncology biological agent
    • Unique mechanism of action
    • Comprehensive IP protection and no competition
    • Successfully completed phase I/IIa clinical trial demonstrating:
      • high safety
      • encouraging clinical benefits for “salvage patients” with actively progressing tumors
      • Elenagen can be used in combination with and enhance other treatment modalities
  • CureLab is seeking investors and/or partners for licensing/M&A:
    • Licensing Elenagen globally or regionally
        • Testing Elenagen in combination with partner’s targeted oncology agent
    • Investment $15 -20 M for completing phase II in the USA and licensing, anticipated time to exit: 36 months

Competition

  • No other company develops a DNA (or a biological agent) based on p62. We were the first, and due to IP protection will remain to be the only anti-cancer p62 biologics.

  • Elenagen does not compete with any other anti-cancer product and/or treatment modality. In contrast, Elenagen will be used in combination with other anti-cancer standards of care (e.g. chemotherapy, radiotherapy, immunotherapies).

Elenagen does not have potential competitors, only potential synergetic partners.